Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
NCT ID: NCT04234620
Last Updated: 2020-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
800 participants
OBSERVATIONAL
2020-02-15
2023-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
NCT04248387
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT04472806
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
NCT04884997
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
NCT04180995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Toripalimab injection
Use of Toripalimab injection in the real world
Toripalimab injection
240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Toripalimab injection
240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients treated with Toripalimab injection;
3. Patients who agreed to participate in this study and signed an informed consent form.
Exclusion Criteria
2. Those who participated in the intervention study of other unapproved drugs / therapies and less than 5 half-lives after the last use of the study drugs.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, , China
The first affiliated Hospital of Jinlin Universtiy
Changchun, , China
Hunan cancer hospital
Changsha, , China
Xiangya Hospital Central South University
Changsha, , China
Chongqing Haijiya Cancer Hospital
Chongqing, , China
Fujian province cancer hospital
Fuzhou, , China
Zhejiang cancer hospital
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Qilu Hospital of Shandong university
Jinan, , China
Shandong province cancer hospital
Jinan, , China
Affiliated Cancer Hospital of Guangxi Medical university
Nanjing, , China
Najing Drum Tower Hospital
Nanjing, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Shanxi Bethune Hopital
Shanxi, , China
The fouth Hospital of Hebei Medical University
Shijiazhuang, , China
The Second affiliated Hospital of Suzhou Universtiy
Suzhou, , China
Tianjin Medical University cancer institute & Hospital
Tianjin, , China
Hubei cancer hospital
Wuhan, , China
Tongji Medical College of Huazhong University of Science & Technology
Wuhan, , China
Wuhan Union Hospital
Wuhan, , China
The first affiliated Hospital of Xiamen Universtiy
Xiamen, , China
Yinchuan Lingke Internet Hosipital
Yinchuan, , China
Affiliated Hopital of Guangdong Medical University
Zhanjiang, , China
Henan cancer hospital
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS001-PMS-CO1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.